SIC
BOLT icon

Salem Investment Counselors’s Bolt Biotherapeutics BOLT Stock Holding History

Salem Investment Counselors’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2
Closed -$11 – 486
2025
Q3 		$11 Hold
2
– – ﹤0.01% 1208
2025
Q2 		$12 Hold
2
– – ﹤0.01% 1166
2025
Q1 		$16 Hold
2
– – ﹤0.01% 1215
2024
Q4 		$22 Hold
2
– – ﹤0.01% 1198
2024
Q3 		$26 Hold
2
– – ﹤0.01% 1181
2024
Q2 		$30 Hold
2
– – ﹤0.01% 1156
2024
Q1 		$56 Hold
2
– – ﹤0.01% 1159
2023
Q4 		$45 Hold
2
– – ﹤0.01% 1098
2023
Q3 		$42 Hold
2
– – ﹤0.01% 1089
2023
Q2 		$52 Hold
2
– – ﹤0.01% 1133
2023
Q1 		$56 Hold
2
– – ﹤0.01% 1102
2022
Q4 		$52 Hold
2
– – ﹤0.01% 1080
2022
Q3 		$0 Hold
2
– – ﹤0.01% 1044
2022
Q2 		$0 Hold
2
– – ﹤0.01% 1076
2022
Q1 		$0 Buy
+2
New +$135 ﹤0.01% 1014

Other funds holding BOLT

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
TC
T3 Companies New York $93.7M AUM
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Salem Investment Counselors's BOLT Position: Q4 2025 in Review

Salem Investment Counselors sold out of Bolt Biotherapeutics (BOLT) in Q4 2025, closing a stake of 2 shares — an estimated $11 sold.

Salem Investment Counselors first reported a position in BOLT in Q1 2022 and held it in 15 quarters. The position peaked at $56 in Q1 2024. 21 funds tracked by Wall St. Rank hold BOLT as of Q4 2025.

  • Salem Investment Counselors reported no remaining Bolt Biotherapeutics position as of Q4 2025 after selling out during the quarter.
  • Salem Investment Counselors sold 2 Bolt Biotherapeutics shares in Q4 2025, an estimated $11.
  • Salem Investment Counselors first reported a position in Bolt Biotherapeutics in Q1 2022 and held it in 15 quarters.
  • Salem Investment Counselors's Bolt Biotherapeutics position peaked at $56 in Q1 2024.
  • 21 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q4 2025.

Based on Salem Investment Counselors's 13F filing for Q4 2025, filed 12 Jan 2026.